Affitope AT06A + adjuvant
/ AFFiRiS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 11, 2021
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
(PubMed, Eur J Clin Pharmacol)
- P1 | "Although both AT04A and AT06 were safe and immunogenic, only AT04A demonstrated significant LDLc-lowering activity, justifying further development."
Clinical • Journal • P1 data • Dyslipidemia • Fatigue • Metabolic Disorders • Musculoskeletal Pain • Pain
1 to 1
Of
1
Go to page
1